zintick

Liquidia LQDA

Liquidia Corp · Nasdaq · Pharmaceutical Preparations

$45.72+0.62%close on Oct. 28, 2026 · volume 2.2M · Yahoo Finance

Price, last 47 sessions

$40.00$60.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 28, 2026 · high $73.67 · low $25.91 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Oct. 26, 2026Dana Boyle
Chief Accounting Officer
Sold
10b5-1 plan
1,581$43.19$68,283
Oct. 26, 2026Jason Adair
Chief Business Officer
Sold
10b5-1 plan
688$43.19$29,715
Oct. 12, 2026Russell Schundler
General Counsel
Sold
10b5-1 plan
13,692$28.48$389,948
Oct. 12, 2026Rajeev Saggar
Chief Medical Officer
Sold
10b5-1 plan
9,218$28.48$262,529
Oct. 12, 2026Scott Moomaw
Chief Commercial Officer
Sold
10b5-1 plan
8,863$28.48$252,418
Oct. 12, 2026Sarah Krepp
Chief Human Resource Officer
Sold
10b5-1 plan
5,245$28.48$149,378
Oct. 12, 2026Sanjeev Khindri
Chief Development Officer
Sold
10b5-1 plan
1,101$28.48$31,356
Oct. 12, 2026Michael Kaseta
CFO and COO
Sold
10b5-1 plan
18,938$28.48$539,354
Oct. 12, 2026Roger Jeffs
Chief Executive Officer, director
Sold
10b5-1 plan
32,744$28.48$932,549
Oct. 12, 2026Dana Boyle
Chief Accounting Officer
Sold
10b5-1 plan
5,892$28.48$167,804
Oct. 12, 2026Jason Adair
Chief Business Officer
Sold
10b5-1 plan
7,301$28.48$207,932
Oct. 5, 2026Stephen M. Bloch
director · indirect
Sold235,477$27.13$6.39 million

Latest 12 of 24. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 27 →
  • 4Oct. 28, 2026, 4:31 p.m. ETView on SEC.gov
  • 4Oct. 28, 2026, 4:30 p.m. ETView on SEC.gov
  • 8-KOct. 13, 2026, 9:49 p.m. ETView on SEC.gov

    Entry into a material definitive agreement · Termination of a material definitive agreement · Regulation FD disclosure · Other events · Financial statements and exhibits

    AI summary, unreviewedLiquidia settles all litigation with United Therapeutics for net $380.7 million in payments, drops PH-ILD indication from YUTREPIA

  • 4Oct. 13, 2026, 8:05 p.m. ETView on SEC.gov
  • 4Oct. 13, 2026, 8:04 p.m. ETView on SEC.gov
  • 4Oct. 13, 2026, 8:03 p.m. ETView on SEC.gov
  • 4Oct. 13, 2026, 8:02 p.m. ETView on SEC.gov
  • 4Oct. 13, 2026, 8:01 p.m. ETView on SEC.gov